Harvard Bioscience shares fall 6.45% in after-hours trading after 2024 financial report shows stable operations.

Harvard Bioscience, Inc. plunged 6.45% in after-hours trading, following the release of its 2024 fiscal year financial report, which indicated the company will continue as a going concern, demonstrating operational stability. The company's products and services in the biotechnology sector cover key applications such as drug and treatment discovery, meeting market demand for life science technologies. Additionally, the stock has seen a 28.15% gain over the past five days, reflecting a rebound in performance.